Medical management of the liver transplant recipient.
Long-term survival of liver transplant recipients has become the rule rather than the exception. As a result, the medical complications of long-term survival, including atherosclerotic cardiovascular disease, metabolic bone disease, and de novo malignancy, have accounted for an increasing proportion of late morbidity and mortality. Risk factors for these complications begin before transplant and are potentially modifiable but are exacerbated by the requirement for immunosuppressive medications after transplantation. Surveillance and early intervention programs administered by transplant hepatologists and other medical subspecialists may improve long-term outcomes in liver transplant recipients by ameliorating risk factors for atherosclerosis, bone fractures, and cancer.
Section of Hepatology, Division of Gastroenterology, Hepatology, and Nutrition, Hume-Lee Transplant Center, Virginia Commonwealth University, Richmond, VA 23298-0341, USA. RSTRAVIT@VCU.EDU
R Todd
RT
Stravitz
Daniel E
DE
Carl
Diane M
DM
Biskobing
D001851:Bone Diseases, Metabolic / Q000209:etiology / Q000628:therapy; D002318:Cardiovascular Diseases / Q000209:etiology / Q000628:therapy; D003324:Coronary Artery Disease / Q000209:etiology / Q000628:therapy; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000628:therapy; D006801:Humans; D006949:Hyperlipidemias / Q000209:etiology / Q000628:therapy; D006973:Hypertension / Q000209:etiology / Q000628:therapy; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015994:Incidence; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000628:therapy; D008107:Liver Diseases / Q000401:mortality / Q000628:therapy*; D016031:Liver Transplantation / Q000009:adverse effects*; D008297:Male; D009369:Neoplasms / Q000209:etiology / Q000628:therapy; D012307:Risk Factors; D016896:Treatment Outcome
D007166:Immunosuppressive Agents